ALL ARI-0001 Brexucabtagene autoleucel IND Crisantaspase Obecabtagene autoleucel Ponatinib IND AML / MDS Cytarabine / daunorubicin (liposomaal) IND Decitabine / cedazuridine Eprenetapopt Glasdegib Imetelstat Ivosidenib Quizartinib Aggressive non-Hodgkin’s lymphoma Acalabrutinib IND Axicabtagene ciloleucel IND Brexucabtagene autoleucel Crizotinib IND Epcoritamab Glofitamab Ibrutinib Mantle cell lymphoma (MCL), 1L. IND Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation IND Lisocabtagene maraleucel Treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after at least two previous lines of treatments. Extension of indication to include treatment of adult patients with Second-line (2L) Transplant Intended (TI) Large B-Cell Lymphoma (LBCL) for Breyanzi. IND Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib IND CLL Acalabrutinib Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients. IND Ibrutinib IND Ublituximab Zanubrutinib Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy IND CML Asciminib Indolent non-Hodgkin’s lymphoma Axicabtagene ciloleucel IND Hypericin Lacutamab Mosunetuzumab Parsaclisib Tisagenlecleucel-T IND Multiple Myeloma Belantamab mafodotin IND Carfilzomib IND Ciltacabtagene autoleucel Daratumumab Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. IND Smouldering multipel myeloom. IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die in aanmerking komen voor een ASCT. IND Elranatamab Idecabtagene vicleucel Isatuximab Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. IND Ixazomib IND Melphalan flufenamide IND Pomalidomide IND Selinexor IND Teclistamab Thalidomide G Venetoclax IND Zevorcabtagene autoleucel Myeloproliferative disorders Bomedemstat Momelotinib Navitoclax Other hematology Lenzilumab Stem cell transplants Narsoplimab Omidubicel Plerixafor G Ruxolitinib IND Tabelecleucel Treosulfan IND UM171